Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides a comprehensive In Vivo CAR-T Development Service leveraging PBAE Nanocomplex Technology to overcome key limitations in non-viral CAR-T engineering. Our platform enables efficient in vivo programming through biodegradable poly(β-amino ester) nanocomplexes designed for high transfection efficiency, T cell selective delivery, and controlled nucleic acid release. We offer full-service support, including construct design, polymer formulation optimization, in vivo delivery strategy development, expression and persistence assessment, and preclinical performance evaluation. This solution minimizes lengthy cell-processing cycles, improves CAR expression consistency, and provides a scalable path toward next-generation non-viral in vivo CAR-T therapeutics.
PBAE nanocomplexes enable biodegradable, non-viral delivery of nucleic acids to circulating T cells, supporting direct in vivo programming of CAR-T cells. Published studies demonstrate effective encapsulation, T-cell targeting via ligand-functionalized polymers, and controlled CAR expression suitable for hematologic and solid tumor models. This technology provides a scalable and versatile alternative to ex vivo manufacturing.
Fig.1 Schematic of the in vivo process for nanoparticle-mediated in situ CAR-T cell therapy.1
Creative Biolabs offers PBAE-based in vivo CAR-T development solutions that enable direct, non-viral gene delivery to circulating T cells using biodegradable nanocomplexes designed for high transfection efficiency and controlled expression kinetics. You can receive customized formulation strategies, optimized targeting ligands, and systematic in vivo evaluation to support discovery, preclinical development, or platform innovation. The service integrates material optimization, T-cell targeting engineering, and functional validation to support both hematologic and solid tumor programs.
Discover How We Can Help - Request a Consultation.
Creative Biolabs provides a comprehensive portfolio of analysis and development platforms supporting In Vivo CAR-T Development with PBAE Nanocomplex Technology. These technologies enable systematic evaluation of polymer-based delivery, in vivo transfection efficiency, immune-cell targeting, and functional CAR-T performance.
| Polymer Design & Nanocomplex Engineering | Targeting, Uptake & In Vivo Delivery Analysis |
|---|---|
|
|
| Functional & Therapeutic Response Evaluation | |
|
|
|
|
Final Deliverables:
Nanocomplex formulation report with characterization data.
In vivo CAR expression and biodistribution analysis.
Functional efficacy and safety evaluation summary.
Creative Biolabs offers in vivo CAR-T development using IVT saRNA technology, enabling amplified, transient CAR expression with reduced dose requirements. This platform supports efficient in-body T-cell programming, enhanced translational safety, and flexible therapeutic modulation without viral vectors.
Creative Biolabs advances in vivo CAR-T therapies through optimized lipid nanoparticle delivery, enabling controlled, non-viral CAR gene expression. This technology supports safer systemic administration, efficient T-cell modification, and robust antitumor activity with strong potential for clinical translation.
How does PBAE nanocomplex delivery compare with lipid-based systems?
PBAE polymers offer biodegradable backbones and tunable charge properties that can enhance endosomal escape. They are suitable for clients seeking customizable, non-viral T-cell delivery platforms.
Can this platform work with both DNA and RNA?
Yes. The system supports plasmid DNA for longer expression or IVT RNA for transient kinetics. Our team can help determine which format aligns with your project goals.
What types of in vivo models are supported?
We support immunodeficient, humanized, and syngeneic models. Recommendations are provided based on the intended CAR target and disease indication.
How is targeting specificity achieved?
Targeting elements such as T-cell-binding fragments or shielding layers can be integrated into the nanocomplex design to improve cell-selective uptake.
Creative Biolabs provides specialized expertise in polymer-based, non-viral delivery systems tailored for immune-cell programming. Our team integrates multidisciplinary formulation capabilities with immuno-oncology insights to design PBAE nanocomplexes that achieve reliable T-cell transfection, controlled expression windows, and reproducible in vivo performance. Supported by Published Data and internal experience, the service offers configurable platforms for exploratory research or preclinical advancement. Contact us to explore the best fit for your application.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
